drug
bezlotoxumab
Marketedupdated 2mo agoby Merck Sharp & Dohme Corp (Inactive)
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying bezlotoxumab
- phase4Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
- phase4Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
- phase3Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
- —Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that